Syndax Pharmaceuticals Inc. (SNDX)

Business: Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.

IPO Date: 03-Mar-2016

CEO & Director: Mr. Michael A. Metzger M.B.A.

Pres, Head of R&D and Director: Dr. Briggs W. Morrison M.D.

Listing: NASDAQ: SNDX

Country: United States

Headquarters: Waltham, MA

Website: https://www.syndax.com

Market cap: $1,075.72 Mln

Revenue (TTM): $139.33 Mln

Earnings (TTM): $15.48 Mln

Cash: $410.91 Mln

Total Debt: $21.02 Mln

Insider's Holding: 5.90%

Liquidity: Low

52 Week range: $13.27 - 22.71

Shares outstanding: 56,232,300

10 Years Aggregate:

• CFO: $-277.20 Mln
• EBITDA: $-342.47 Mln
• Net Profit: $-351.60 Mln